(Q36178329)

English

Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis.

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22928118%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22928118%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

based on heuristic

inferred from title

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22928118%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

A Hilliard

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22928118%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

C Stott

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22928118%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

S Wright

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22928118%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

G Guy

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22928118%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

S Al-Izki

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22928118%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

C Bolton

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22928118%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

G Giovannoni

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22928118%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

publication date

7 August 2012

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22928118%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22928118%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

2012

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22928118%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

802649

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22928118%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

copyright license

Creative Commons Attribution 3.0 Unported

7 August 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

1 reference

April 2022 Public Data File from Crossref

A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423911

1 October 2017

THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423911

1 October 2017

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423911

1 October 2017

Neuropharmacology and therapeutic potential of cannabinoids

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423911

1 October 2017

The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423911

1 October 2017

Endocannabinoid signaling as a synaptic circuit breaker in neurological disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423911

1 October 2017

Cannabinoid control of neuroinflammation related to multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423911

1 October 2017

The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423911

1 October 2017

Intrathecal baclofen therapy in patients with severe spasticity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423911

1 October 2017

Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423911

1 October 2017

Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423911

1 October 2017

Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423911

1 October 2017

A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423911

1 October 2017

Treatments for spasticity and pain in multiple sclerosis: a systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423911

1 October 2017

CB1 cannabinoid receptors and on-demand defense against excitotoxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423911

1 October 2017

International Union of Pharmacology. XXVII. Classification of cannabinoid receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423911

1 October 2017

Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423911

1 October 2017

Endocannabinoids control spasticity in a multiple sclerosis model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423911

1 October 2017

Anti-spasticity agents for multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423911

1 October 2017

Cannabinoids control spasticity and tremor in a multiple sclerosis model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423911

1 October 2017

Treatment of Human Spasticity with Δ9-Tetrahydrocannabinol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423911

1 October 2017

Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423911

2 July 2018

Prolonged episode of dystonia and dyskinesia resembling status epilepticus following acute intrathecal baclofen withdrawal.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423911

23 September 2018

A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423911

23 September 2018

Baclofen withdrawal causes psychosis in otherwise unclouded consciousness

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423911

23 September 2018

Medicinal cannabis: is delta9-tetrahydrocannabinol necessary for all its effects?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423911

23 September 2018

Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB(1)/CB(2) receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423911

23 September 2018

Nabilone in the treatment of multiple sclerosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423911

23 September 2018

Cannabis and Cannabis Extracts

1 reference

https://api.crossref.org/works/10.5402%2F2012%2F802649

21 January 2018

Muscle stiffness and continuous electromyographic activity in old rats; an animal model for spasticity?

1 reference

https://pubmed.ncbi.nlm.nih.gov/22928118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction of chronic relapsing experimental allergic encephalomyelitis in Biozzi mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/22928118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cannabinoids and multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22928118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22928118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic baclofen abuse and withdrawal delirium

1 reference

https://pubmed.ncbi.nlm.nih.gov/22928118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Delta-9-THC in the treatment of spasticity associated with multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22928118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Altered motor control and spasticity after spinal cord injury: subjective and objective assessment

1 reference

https://pubmed.ncbi.nlm.nih.gov/22928118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.5402/2012/802649

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22928118%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22928118%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22928118%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36178329&oldid=1955191143"